19:34 , May 17, 2018 |  BC Innovations  |  Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
21:13 , Apr 17, 2018 |  BC Innovations  |  Distillery Techniques

Disease models; drug properties

TECHNOLOGY: 3-D models; pharmacokinetics/pharmacodynamics 3-D human intestinal organoids could be used to test the PK properties of drug compounds. The organoids are generated by culturing human induced pluripotent stem (iPS) cells in a medium containing fibroblast...
18:00 , Aug 16, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Self-assembling multicellular BBB spheroids could help screen compounds for BBB permeability. The spheroids self-assembled from co-cultures of primary human astrocytes, brain vascular pericytes and either brain microvascular endothelial cells or a human cerebral...
17:54 , Jul 26, 2017 |  BC Innovations  |  Emerging Company Profile

Breaching the gates

Junction Therapeutics Ltd.’s siRNA-based technology creates transient openings in the blood-brain barrier by targeting tight junction proteins, allowing molecules to move in and out of the brain by diffusion. The approach enhances entry of therapies...
08:00 , Dec 3, 2015 |  BC Innovations  |  Translation in Brief

IL-17A's autoimmune dichotomy

A pair of studies has resolved the conundrum of why blocking IL-17A helps in psoriasis but exacerbates Crohn's disease, and highlights the dangers of assuming that hitting a target in autoimmunity will have the same...
07:00 , Oct 8, 2015 |  BC Innovations  |  Translation in Brief

Holey BBB

A study from Trinity College Dublin has shown that reducing the levels of two tight junction proteins can loosen the blood-brain barrier and let soluble β-amyloid monomers slip out of the brain through the spaces...
07:00 , Oct 1, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Claudin 5 (CLDN5); occludin (OCLN); β amyloid (Aβ)

Neurology INDICATION: Alzheimer's disease (AD) In vitro and mouse studies suggest inhibiting CLDN5 and OCLN could help treat AD. In endothelial cell cultures, knockdown of both CLDN5 and OCLN increased paracellular diffusion of Aβ monomers across cell...
07:00 , Sep 5, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

Approach Summary Licensing status Publication and contact information Disease models Transgenic, humanized mouse model of HCV infection Partially immunocompromised, humanized mice could be used as a model of HCV...
07:00 , Jun 16, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models Immunocompetent, humanized mouse model for HCV infection An immunocompetent, humanized mouse model of HCV...
07:00 , Jun 16, 2011 |  BC Innovations  |  Cover Story

HCV's mighty mouse

The most widely used animal model of HCV infection requires transplanting human hepatocytes into immunodeficient mice. These mice are useful for testing antivirals, but the absence of an immune system makes the animals unsuitable for...